CIC
AZN icon

Carnegie Investment Counsel’s AstraZeneca AZN Stock Holding History

Carnegie Investment Counsel’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Hold
6,895
– – 0.03% 287
2026
Q1 		$1.36M Buy
6,895
+430
+7% +$82.9K 0.03% 291
2025
Q4 		$1.19M Sell
6,465
-503
-7% -$88.2K 0.02% 306
2025
Q3 		$1.07M Hold
6,968
– – 0.02% 308
2025
Q2 		$974K Sell
6,968
-1,606
-19% -$225K 0.02% 309
2025
Q1 		$1.13M Buy
8,574
+328
+4% +$47.5K 0.03% 274
2024
Q4 		$1.08M Sell
8,246
-423
-5% -$59.2K 0.03% 258
2024
Q3 		$1.35M Buy
8,669
+34
+0.4% +$5.49K 0.04% 242
2024
Q2 		$1.35M Buy
8,635
+69
+0.8% +$10.4K 0.04% 240
2024
Q1 		$1.16M Sell
8,566
-341
-4% -$45.2K 0.04% 275
2023
Q4 		$1.2M Sell
8,907
-9
-0.1% -$1.17K 0.04% 259
2023
Q3 		$1.21M Sell
8,916
-5
-0.1% -$683 0.05% 247
2023
Q2 		$1.28M Sell
8,921
-10
-0.1% -$1.47K 0.05% 255
2023
Q1 		$1.24M Buy
8,931
+226
+3% +$30.4K 0.05% 263
2022
Q4 		$1.18M Buy
8,705
+129
+2% +$16.2K 0.05% 257
2022
Q3 		$941K Buy
8,576
+332
+4% +$42.1K 0.04% 273
2022
Q2 		$1.09M Sell
8,244
-125
-1% -$16.4K 0.05% 249
2022
Q1 		$1.11M Sell
8,369
-549
-6% -$65.8K 0.04% 257
2021
Q4 		$1.04M Buy
8,918
+51
+0.6% +$6K 0.03% 269
2021
Q3 		$1.06M Hold
8,867
– – 0.04% 239
2021
Q2 		$1.06M Buy
+8,867
New +$973K 0.04% 246
2020
Q4 		– Sell
-1,835
Closed -$201K – 428
2020
Q3 		$201K Buy
+1,835
New +$204K 0.01% 395
2018
Q4 		– Sell
-2,986
Closed -$244K – 370
2018
Q3 		$244K Buy
+2,986
New +$226K 0.02% 316

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Carnegie Investment Counsel's AZN Position: Q2 2026 in Review

Carnegie Investment Counsel held its AstraZeneca (AZN) position steady in Q2 2026 at 6,895 shares worth $1.31M. The position accounts for 0.03% of the portfolio, ranked #287.

Carnegie Investment Counsel first reported a position in AZN in Q3 2018 and has held it in 23 quarters since. The position peaked at $1.36M in Q1 2026. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Carnegie Investment Counsel held 6,895 shares of AstraZeneca worth $1.31M as of Q2 2026.
  • Carnegie Investment Counsel left its AstraZeneca share count unchanged in Q2 2026.
  • AstraZeneca made up 0.03% of Carnegie Investment Counsel's portfolio in Q2 2026, its #287 holding.
  • Carnegie Investment Counsel first reported a position in AstraZeneca in Q3 2018 and has held it in 23 quarters since.
  • Carnegie Investment Counsel's AstraZeneca position peaked at $1.36M in Q1 2026.
  • 906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.